
==== Front
Open Forum Infect Dis
Open Forum Infect Dis
ofid
Open Forum Infectious Diseases
2328-8957
Oxford University Press US

10.1093/ofid/ofae471
ofae471
Review Article
AcademicSubjects/MED00290
Editor's Choice
The Role of the Gut, Urine, and Vaginal Microbiomes in the Pathogenesis of Urinary Tract Infection in Women and Consideration of Microbiome Therapeutics
Naji Amal Piedmont Hospital, Atlanta, Georgia, USA

Siskin Drew Emory University, Atlanta, Georgia, USA

https://orcid.org/0000-0002-6181-4599
Woodworth Michael H Division of Infectious Diseases, Department of Medicine, Emory University, Atlanta, Georgia, USA

Lee John R Division of Nephrology and Hypertension, Weill Cornell Medicine, New York, New York, USA

https://orcid.org/0000-0003-1757-8477
Kraft Colleen S Division of Infectious Diseases, Department of Medicine, Emory University, Atlanta, Georgia, USA
Department of Pathology and Laboratory Medicine, Emory University, Atlanta, Georgia, USA

https://orcid.org/0000-0001-6324-0077
Mehta Nirja Division of Infectious Diseases, Department of Medicine, Emory University, Atlanta, Georgia, USA

Amal Naji and Drew Siskin co-first authors.

Potential conflicts of interest. Dr. Lee holds patent 2020-0048713-A1, “Methods of Detecting Cell-Free DNA in Biological Samples,” licensed to Eurofins Viracor. He additionally has received an investigator-initiated grant from BioFire Diagnostics, LLC, and an honorarium for a talk from Astellas. Finally, he is also on the board of directors for the Chinese American Medical Society. Dr. Kraft is a consultant for Rebiotix/Ferring and on the scientific advisory board of Seres Therapeutics and Vedanta Biosciences. All other authors have no conflicts of interest to disclose.

Correspondence: Nirja Mehta, MD, Division of Infectious Diseases, Department of Medicine, Emory University, 550 Peachtree St NE Medical Office Tower Fl 7, Atlanta, GA 30308, USA (nirja.mehta@emory.edu).
9 2024
19 8 2024
19 8 2024
11 9 ofae47112 6 2024
02 8 2024
15 8 2024
06 9 2024
© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
2024
https://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The gut, urine, and vaginal microbiomes play significant roles in the pathogenesis of recurrent urinary tract infections (rUTIs). Analysis of these microbiota has shown distinct associations with urinary tract infections. Encouraging data indicate that rUTIs may be responsive to microbiome treatments such as fecal microbiota transplantation, expanding potential treatments beyond antibiotics, hydration, and behavioral interventions. If successful, these nonantibiotic therapies have the potential to increase time between rUTI episodes and reduce the prevalence of multidrug-resistant organisms. In this review, we discuss the role of the 3 microbiomes in the pathogenesis of rUTI and utilization of live biotherapeutic products as therapy for rUTI.

This review discusses the role of the gut, urine and vaginal microbiome on recurrent urinary tract infection pathogenesis, as well as how live biotherapeutic products such as fecal microbiota transplantation can influence the microbiome and affect clinical outcomes

bacteria
gut
microbiome
urinary
vaginal
==== Body
pmcRecurrent urinary tract infections (rUTIs) increase morbidity and diminish quality of life due to their recurrent nature, impact on sexual relationships, and chronic discomfort [1, 2]. These infections are typically defined as at least 2 episodes of UTIs within 6 months or 3 episodes within 12 months [3]. Numerous approaches have been explored to identify mechanisms that perpetuate rUTIs that may be amenable to therapeutic development. In 2008, the Human Microbiome Project (HMP) was launched to understand the contribution of microbial composition to human health and disease [4]. Initially, the urinary system was not included in this project because it was thought to be sterile. However, the development of improved culturing methods revealed that the urinary system harbors a distinct microbiome [4, 5].

The pathogenesis of UTIs begins with the introduction of virulent bacteria of the urinary system, referred to as uropathogens [6]. Most uropathogens are of gastrointestinal origin; however, data also demonstrate an important role of the vaginal and urine microbiomes in the development of recurrent UTIs [7–9]. A large study of 435 cultured urine specimens found that approximately two-thirds of these bacteria were shared with the human gut repertoire, and one-third with the human vaginal repertoire. This finding underscores the important contributions of both populations to the commensal bacteria of the urine microbiome in women [7]. Given the rising prevalence of antibiotic-resistant organisms (a subset of which are known as multidrug-resistant organisms [MDROs]) and limited treatment options, researchers have focused on finding novel strategies to treat recurrent UTIs [10]. This review will describe existing data regarding the interplay of the gut, urine, and vaginal microbiomes in driving rUTIs and the impact of microbiota therapeutics such as fecal microbiota transplantation (FMT) on the frequency and causative pathogens of urinary tract infections and the antibiotic susceptibility of the various uropathogens implicated in UTIs.

METHODS

We conducted a PubMed query by searching for keywords including “gut microbiome,” “urine microbiome,” “vaginal microbiome,” “recurrent urinary tract infection,” and “antibiotic resistant urinary tract infection.” Our search yielded 523 papers. Two authors (A.N. and D.S.) reviewed the papers, then filtered them to include papers that highlight the role of gut, urine, and vaginal microbiomes, and their potential role in urinary tract infections. We included only human studies on populations greater than 18 years of age. At this point, only 40 studies remained. These 40 papers included systematic reviews, literature reviews, retrospective studies, case reports, and prospective/retrospective case studies.

Gut Microbiome and Urinary Tract Infections

The gut bacteria play an important role in urinary tract infections. Several studies have evaluated the impact of the competitive ecosystem in the gut on the thriving of uropathogens such as Enterobacteriaceae [11–13]. In a study by Magruder et al., the prevalence of Faecalibacterium and Romboutsia, regarded as commensal bacterial taxa, was significantly elevated in the kidney transplant recipients who did not develop Enterobacteriaceae bacteriuria as compared with kidney transplant recipients who did [11]. In a case–control study of children, the gut abundance of Enterobacter spp. in children with febrile UTIs was higher than healthy children, specifically with a higher relative abundance of Escherichia coli in patients with UTIs [14].

Several different mechanisms may explain the function of commensal bacteria in resisting uropathogen gut colonization, such as direct production of bacteriocin, depletion of nutrients, and production of short-chain fatty acids (SCFAs) [12]. The production of the peptide bacteriocin confers a bactericidal effect on pathogenic bacteria such as Enterobacteriaceae. It inhibits cell wall synthesis and disrupts the bacterial membrane by forming pores [15]. Additionally, SCFAs, a product of gut fermentation, often lead to an acidic intracellular medium. The SCFA-mediated acidic milieu inhibits the replication of uropathogenic organisms such as E. coli, Klebsiella pneumoniae, and other members of the Enterobacteriaceae by decreasing the availability of oxygen and nitrate. SCFAs were also found to stabilize hypoxia-inducible factor–1 (HIF-1), thus increasing production of antimicrobial proteins. The decrease in the abundance of these organisms in the intestines secondary to the production of bacteriocin and SCFA decreases the risk of bacteriuria and likely urinary tract infections [12].

Fecal Microbiota Transplantation and Recurrent Urinary Tract Infections

Given the strong relationship between the gut microbiome and etiologic agents of UTIs, several studies have evaluated the use of FMT in the treatment of rUTIs [16–18]. FMT increases the alpha diversity of the gut, reducing the relative abundance of uropathogens, and has also been shown to reduce urinary tract infections [19]. However, no consensus has been established regarding the routine utilization of FMT to treat rUTIs in general or UTIs due to multidrug-resistant organisms, and the Food and Drug Administration (FDA) has not approved the use of FMT in the treatment of urinary tract infections [20]. Most studies published regarding the use of FMT in the treatment of UTIs are case reports and case series (Table 1) [16–18, 21–27]. Most of these studies have shown complete resolution of UTI symptoms and a decrease in the prevalence of uropathogens for up to 1 year after FMT. Moreover, a study by Tariq et al. reported a significant 4-fold reduction in the frequency of urinary tract infections 1 year after FMT. An additional study by the same group also reported a reduction in UTIs after patients were treated with FMT for recurrent Clostridioides difficile infection. These reductions were largely attributed to the ability of FMT to replenish the healthy gut microbiome, thus replacing uropathogens and decreasing the risk of UTIs [17, 28]. None of these studies reported severe or life-threatening adverse events, thus suggesting that FMT could be a safe decolonization modality [16–18, 21–24].

Table 1. Fecal Microbiota Transplantation in the Treatment of Urinary Tract Infections

Authors	Patients’ Characteristics	Type of Study	Primary End Point	Outcome	Adverse Events	
Aira et al., 2020 [21]	93-year-old female with history of recurrent UTIs, chronic hepatitis C, end sigmoid colostomy for acute diverticulitis, and recurrent C. difficile; 3 UTIs in the past year	Case report	Efficacy of FMT in treatment of recurrent C. difficile infection	No symptoms of C. difficile infection after a year
No new symptomatic UTIs after 1 year
Reduction in Enterobacteriaceae in gut post-FMT	None	
Jeney et al., 2020 [16]	Ten women with recurrent refractory urinary tract infections	Prospective case series	Comparison of number of UTIs 6 months before enema-based FMT with number of UTIs 6 months post-FMT	Nonsignificant decrease in the number of symptomatic UTIs; out of 10, 4 women no longer met criteria for rUTIs, and 3 had no further UTIS	None	
Ramos-Martinez et al., 2020 [22]	43-year-old patient with recurrent C. difficile infection and rUTI	Case report	Efficacy of FMT in treatment of recurrent C. difficile	No new episodes of C. difficile or UTI 10 months post-FMT	None	
Hocquart et al., 2019 [23]	73-year-old woman with irritable bowel syndrome and recurrent urinary tract infections	Case report	Efficacy of FMT in reducing frequency of stools and improving stool consistency	No recurrence of UTIs; decrease in IBS symptoms after FMT	None	
Biehl et al., 2018 [18]	43-year-old kidney transplant recipient with recurrent UTIs	Case report	Efficacy of FMT in treatment of recurrent UTIs	No new UTI symptoms 9 months after FMT; decrease in Enterobacteriaceae over time	None	
Wang et al., 2018 [24]	83-year-old woman with 25-year history of recurrent urinary tract infections	Case report	Efficacy of FMT in treatment of recurrent C. difficile infections and recurrent UTIs	Complete resolution of UTI and C. difficile infection 9 months after FMT	None	
Stalenhoef et al., 2017 [25]	34-year-old woman with Verona integron–encoded metallo-β-lactamase-induced recurrent urinary tract infections	Case report	Efficacy of FMT in reduction of MDR stains in stool	Persistence of ESBL- producing E. coli in stool after FMT
No significant difference in microbial diversity after FMT	Loose stools for 3 days	
Staley et al., 2017 [26]	19 patients who underwent FMT for treatment of recurrent C. difficile infection	Case series	Efficacy of aminoglycoside-based outpatient UTI treatment regimen in	Resolution of UTI symptoms
No recurrence of C. difficile	Tenderness over gluteal muscles	
…	…	…	preservation of gut integrity	No significant difference in alpha diversity of gut after treatment with aminoglycosides	…	
Tariq et al., 2017 [17]	8 patients with recurrent UTIs who underwent FMT	Retrospective case series	Efficacy of FMT in reducing the frequency of UTIs cause by MDRO	4-fold reduction in the median frequency of UTIs post-FMT
No recurrence of C. difficile infection at 1 year post-transplant
Decrease in frequency of MDR organisms causing UTIs	None	
Singh et al., 2014 [27]	60-year-old male post–renal transplant with recurrent pyelonephritis caused by ESBL-producing E. coli	Case report	Efficacy of FMT in decolonizing patient from ESBL	Negative rectal cultures for ESBL at 12 weeks post follow-up
No symptoms of UTI	Mild diarrhea and abdominal cramps	
Abbreviations: ESBL, extended-spectrum beta-lactamase; FMT, fecal microbiota transplantation; IBS, irritable bowel syndrome; MDRO, multidrug-resistant organism; UTI, urinary tract infection.

Fecal Microbiota Transplantation and Antibiotic Susceptibility

The emergence of MDROs has been a major public health concern [29–31]. The gut has been identified as a reservoir for MDROs, constituting the “resistome” for both pathogenic and nonpathogenic bacteria [29, 32]. Intestinal colonization by these organisms was found to precede several invasive infections including rUTI, thus contributing to an increase in morbidity and mortality [33]. Therefore, gut decolonization through FMT has been proposed as a promising approach to diminish such infections. The eradication of MDROs occurs by increasing the phylogenetic diversity of the gut microbiome with an increase in the frequency of commensal bacteria and decrease in the frequency of pathogenic bacteria such as Enterobacteriaceae [30, 31].

Recently, several studies have evaluated the safety and efficacy of FMT in eradicating MDRO colonization, with somewhat mixed results [34–36]. A study by Seong et al. demonstrated that patients undergoing FMT were found to have a 68.6% decolonization rate of carbapenemase-producing Enterobacteriaceae (CPE) and vancomycin-resistant enterococci (VRE) within a year after transplant compared with only 27.1% of patients who did not receive an FMT [34]. This was shown to be inconsistent with data reported in a systematic review by Yoon et al., which showed a nonsignificant difference in the eradication rates of the various MDROs such as CPE, VRE, and extended spectrum beta-lactamase (ESBL)–producing Enterobacteriaceae [35]. Similarly, Stalenhoef et al. attributed the nonsignificant reduction in the UTI episodes to the failure of FMT to clear ESBL E. coli [25]. A recent randomized controlled trial (RCT) investigating the role of FMT in MDRO decolonization in renal transplant recipients demonstrated that FMT can potentially support bacterial strain replacement of resistant organisms [37]. Hyun et al. found that FMT downregulated various resistance genes including vanA and blaKPc, thus enhancing antibiotic susceptibility [38]. The success of FMT in rUTIs has been associated with several factors, including, but not limited to, treatment with antibiotics before or after FMT, frequency of FMT, host characteristics, and characteristics of the MDROs [35, 39–41]. However, no concrete recommendations for FMT administration for rUTIs have been established to date. It is worth noting that studies have demonstrated acquisition of donor-derived antimicrobial-resistant genes through FMT, emphasizing the importance of developing appropriate screening programs to identify healthy stool donors in the success of FMT [42–44]. However, Leung et al. reported the acquisition of donor-derived antimicrobial-resistant genes through FMT. This further emphasizes the importance of developing appropriate screening programs to identify healthy stool donors in the success of FMT [44].

Limited studies evaluating the efficacy of FMT in the eradication of MDROs in in vivo models exist in the literature [45, 46]. In a study by Mrazek et al., murine models infected with multidrug-resistant Pseudomonas aeruginosa underwent FMT from either human or mouse fecal donors. FMT, irrespective of the source of the donated fecal samples, significantly decreased the load of MDROs [45]. The introduction of commensal bacteria allows for clearance of MDROs at different rates [46].

Urine Microbiome

The urinary tract was not included in early microbiome research because urine was thought to be naturally sterile [10, 47, 48]. This hypothesis has since been rejected by the introduction of high-throughput sequencing. Acknowledging the technical limitations of sequencing low-biomass specimens and potential contamination, urine sequencing analyses have detected a wide diversity of bacteria in the urine of asymptomatic healthy individuals [6, 8]. The urinary tract has been shown to host a complex microbial community. This community includes core bacterial genera, which are often altered by diseases and infections. In general, both female and male urine microbiomes have been found to be dominated by the phylum Firmicutes [48]. To date, what most studies have focused on analyzing is the female urine microbiome due to the higher incidence of urological disorders in women. Females have been found to have a heterogenous mix of bacterial genera compared with males [48–50]. An analysis of catheterized urine samples from premenopausal and postmenopausal women showed that the samples were largely dominated by the Lactobacillus genus. Other bacterial genera isolated included Gardnerella, Prevotella, Escherichia-Shigella, Atopobium, Streptococcus, and Dialister. The variation in the bacterial composition of the urine microbiome is often determined by multiple factors, including age, ethnicity, sexual activity, and hormonal changes [49].

The urine microbiota profile often plays a substantial role in predicting the risk of urinary tract disorders. The relative abundance of certain bacterial taxa has been found to predict future risk of bladder dysbiosis. For example, women with a lower relative abundance of Lactobacillus were found to have an increased risk of bladder disorders including urinary incontinence [49]. Moreover, a disruption in the diversity of the urine microbiome is implicated in the pathogenesis of rUTIs [8]. This occurs via various mechanisms including migration of resistant uropathogenic bacteria from the gut, re-infection from an external source, or bacteria persistent in the urothelium [16]. Taxonomic profiling of the various human microbiomes has shown a significant overlap between the urine, gut, and vaginal microbiomes. Dubourg et al. identified bacteria in the urine using the 16S rRNA gene sequencing method. Of those bacterial species, 64.1% were found to be shared with the human gut microbiome. Therefore, the origin of bacterial constituents of the urine microbiome was found to be mostly of gastrointestinal origin [6].

While antibiotic therapy remains the mainstay treatment for UTIs, conventional antibiotics often cause long-term modifications in the urine microbiome, recurrent cystitis, and rise in MDROs [10, 51]. Then, these organisms frequently persist in the bladder by formation of intracellular bacterial communities, typically within a biofilm-like structure. Biofilms can further contribute to antibiotic resistance by degrading antibiotics or utilizing beta-lactamases. In the elderly and immunocompromised population, the uropathogenic reservoirs are commonly polymicrobial; therefore, inappropriate antibiotic intervention can have detrimental effects on resistance [10, 51, 52].

Urine Virome

An analysis of the viral constituents of the urinary tract revealed the essential role that lytic phages play in treating multidrug-resistant organisms (MDROs). This effectiveness is largely attributed to the production of lytic proteins, including endolysins and virion-associated peptidoglycan hydrolases, which lead to the lysis of bacterial cell walls [10].

Urine Mycobiome

Research on microbial communities associated with urinary tract infections has predominantly focused on studying bacteria. Consequently, nonbacterial components of the urinary system have been largely understudied. Previously, there was a misconception that these organisms play a minor role in the development of urinary tract infections. Among the fungi detected in urine, species from the Saccharomyces class, such as Saccharomyces and Candida, were identified [53, 54]. Studies have demonstrated that changes in the host's immune state can significantly contribute to fungal colonization and pathology in the urinary tract system. The urinary mycobiome in other diseases, such as interstitial cystitis, has been better characterized and is being increasingly appreciated in its role for other urologic disorders [55].

Vaginal Microbiome

While the gut is most considered the reservoir for enteropathogens leading to UTI, increasing research demonstrates that the vaginal microbiome also plays an essential role in the pathogenesis of UTIs in women [9, 56, 57]. Over 460 species of bacteria have been described in vaginal microbiome studies [58]. The urine microbiome shares up to one-third of microbial species with the vaginal microbiome. Increasing data demonstrate that the pathogenesis of recurrent UTIs is influenced by the vaginal microenvironment in addition to the gut microenvironment [59]. When the vaginal microbiome is disturbed or altered, the risk for UTIs increases [9, 60]. Sexual activity and douching are some of the strongest independent risk factors for the development of UTIs in women, further demonstrating the close link between the vaginal and urinary microbiota and implicating frequent mechanical transfer of bacteria between vaginal and urinary mucosal sites [61]. Lactobacillus, the most common species in the vaginal microbiome in women of reproductive age, produces bacteriocins and hydrogen peroxide that protect against colonization of various pathogens, including E. coli [62]. Dysbiosis of the microbiome and decreased population of Lactobacillus have been implicated in other disease states such as bacterial vaginosis and Neisseria gonorrhoeae infection, in addition to higher rates of UTI [57, 62, 63].

The role of the vaginal microbiome in the facilitation of E. coli colonization and pathogenesis of the bladder has been noted in several studies. In a study of 77 women, E. coli strains from the vagina and urine were 99.72% similar by whole-genome pairwise average nucleotide identity [64]. Patients with a history of UTI have been found to have higher levels of E. coli colonization in the vagina and urine compared with patients without a history of UTI [65]. Additionally, commensal vaginal bacteria such as Gardnerella vaginalis may transiently enter the bladder, leading to egress from latent bladder reservoirs, leading to UTI in murine models [61]. Gardnerella vaginalis and Group B Streptococcus have been implicated in a process termed “covert pathogenesis,” by which the transient presence of these organisms early in infection leads to immunomodulation, which may increase susceptibility to clinical infection by more traditional uropathogens such as E. coli [57, 61]. Additionally, the hormone changes during menopause change the vaginal microbiome and decrease the amounts of Lactobacillus species, increasing rates of rUTIs and UTIs [60]. Topical estrogen has long been recommended to postmenopausal women with recurrent UTIs, with multiple studies demonstrating lower UTI rates in patients after estrogen use [66]. In a large cohort study of postmenopausal women, vaginal colonization with E. coli was more frequent in women without estrogen replacement [67]. Estrogen replacement leads to higher levels of Lactobacillus in this population, thereby creating a microbiome that is more resistant to colonization by uropathogens [64, 67].

While microbiome therapeutics are common in the gut microbiome with FMT, manipulation of the vaginal microbiome is less well studied. In a double-blind placebo- controlled trial that enrolled 100 premenopausal women with at least 1 UTI in the past 12 months, patients who received Lactobacillus crispatus suppositories, a species that produces high quantities of H2O2, demonstrated that higher quantities of L. crispatus colonization were associated with lower levels of rUTI [60]. Moreover, the use of vaginal and oral probiotics has been shown to have a promising role in decreasing recurrent urinary tract infections in women. They have been shown to halt the ascension of uropathogens by interfering with pathogen adhesion, biofilm formation, and expression of virulence factors. They were also shown to modulate the host's defense against uropathogens [68]. Given these results, further studies evaluating the role of fortification of the vaginal microbiome in preventing UTIs are needed. At present, the focus exclusively on the gut microbiome (using FMT and other microbiome products) may only be addressing part of the full mechanism driving rUTIs.

Interaction Between Urine, Gut, and Vaginal Microbiomes

The urine, vaginal, and gut microbiomes are interconnected and interact with one another. The exchange and interaction of organisms between these microbiomes contribute to urinary tract infections. Bacteria from the gut are influential in infections occurring higher up in the urinary system, whereas bacteria from the vaginal microbiome are often involved in infections in the lower urinary tract. Hence, identifying factors that influence these microbiomes is crucial in efforts to reduce the incidence of urinary tract infections [9].

CONCLUSIONS

The gut, urine, and vaginal microbiomes play an important role in the pathogenesis of UTIs and rUTIs. Historically, antibiotics were the sole treatment for managing urinary tract infections. However, the emergence of multidrug-resistant organisms has prompted exploration of more innovative approaches, such as vaginal probiotics and fecal microbiota transplant. These treatments have shown promising results and hopefully will offer effective alternatives in combating urinary tract infections, especially in cases where traditional antibiotic therapies may be less effective due to resistance issues.

Acknowledgments

Financial support. No funding to disclose.
==== Refs
References

1 Foxman B . The epidemiology of urinary tract infection. Nat Rev Urol 2010; 7 :653–60.21139641
2 Vazquez-Montes M , FanshaweTR, StoesserN, et al Epidemiology and microbiology of recurrent UTI in women in the community in oxfordshire, UK. JAC Antimicrob Resist 2024; 6 :dlad156.38204597
3 Peck J , ShepherdJP. Recurrent urinary tract infections: diagnosis, treatment, and prevention. Obstet Gynecol Clin North Am 2021; 48 :501–13.34416934
4 Turnbaugh PJ , LeyRE, HamadyM, et al The Human Microbiome Project. Nature 2007; 449 :804–10.17943116
5 Tang J . Microbiome in the urinary system—a review. AIMS Microbiol 2017; 3 :143–54.31294154
6 Tabibian JH , GornbeinJ, HeidariA, et al Uropathogens and host characteristics. J Clin Microbiol 2008; 46 :3980–6.18842936
7 Dubourg G , MorandA, MekhalifF, et al Deciphering the urinary microbiota repertoire by culturomics reveals mostly anaerobic bacteria from the gut. Front Microbiol 2020; 11 :513305.33178140
8 Morand A , CornuF, DufourJ-C, et al Human bacterial repertoire of the urinary tract: a potential paradigm shift. J Clin Microbiol 2019; 57: e00675-18.
9 Meštrović T , MatijašićM, PerićM, et al The role of gut, vaginal, and urinary microbiome in urinary tract infections: from bench to bedside. Diagnostics (Basel) 2020; 11 :7.33375202
10 Kenneally C , MurphyCP, SleatorRD, et al The urinary microbiome and biological therapeutics: novel therapies for urinary tract infections. Microbiol Res 2022; 259 :127010.35338973
11 Magruder M , SholiAN, GongC, et al Gut uropathogen abundance is a risk factor for development of bacteriuria and urinary tract infection. Nat Commun 2019; 10 :5521.31797927
12 Sorbara MT , DubinK, LittmannER, et al Inhibiting antibiotic-resistant Enterobacteriaceae by microbiota-mediated intracellular acidification. J Exp Med 2019; 216 :84–98.30563917
13 Gerritsen J , HornungB, RenckensB, et al Genomic and functional analysis of Romboutsia ilealis CRIB(T) reveals adaptation to the small intestine. PeerJ 2017; 5 :e3698.28924494
14 Paalanne N , SaloJ, PieviläinenO, et al Intestinal microbiome as a risk factor for urinary tract infections in children. Eur J Clin Microbiol Infect Dis 2018; 37 :1881–91.30006660
15 Corr SC , LiY, RiedelCU, et al Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. Proc Natl Acad Sci U S A 2007; 104 :7617–21.17456596
16 Jeney SES , LaneF, OliverA, et al Fecal microbiota transplantation for the treatment of refractory recurrent urinary tract infection. Obstet Gynecol 2020; 136 :771–3.32925627
17 Tariq R , PardiDS, ToshPK, et al Fecal microbiota transplantation for recurrent Clostridium difficile infection reduces recurrent urinary tract infection frequency. Clin Infect Dis 2017; 65 :1745–7.29020210
18 Biehl LM , Cruz AguilarR, FarowskiF, et al Fecal microbiota transplantation in a kidney transplant recipient with recurrent urinary tract infection. Infection 2018; 46 :871–4.30109576
19 Jeney SES , Avelar-BarraganJ, WhitesonK, et al Fecal putative uropathogen abundance and antibiotic resistance gene carriage in women with refractory recurrent urinary tract infection treated with fecal microbiota transplantation. Female Pelvic Med Reconstr Surg 2022; 28 :213–9.34608030
20 Schiereck T , YeldanS, KranzJ, et al Urinary bladder microbiome analysis and probiotic treatment options for women with recurrent urinary tract infections. Urologe A 2022; 61 :41–51.34424357
21 Aira A , RubioE, Vergara GómezA, et al rUTI resolution after FMT for Clostridioides difficile infection: a case report. Infect Dis Ther 2021; 10 :1065–71.33136261
22 Ramos-Martínez A , Martínez-RuizR, Múñez-RubioE, et al Effect of faecal microbiota transplantation on recurrent urinary tract infection in a patient with long-term suprapubic urinary catheter. J Hosp Infect 2020; 105 :332–3.32004516
23 Hocquart M , PhamT, KueteE, et al Successful fecal microbiota transplantation in a patient suffering from irritable bowel syndrome and recurrent urinary tract infections. Open Forum Infect Dis 2019; 6:ofz398.
24 Wang T , KraftCS, WoodworthMH, et al Fecal microbiota transplant for refractory Clostridium difficile infection interrupts 25-year history of recurrent urinary tract infections. Open Forum Infect Dis 2018; 5:ofy016.
25 Stalenhoef JE , TerveerEM, KnetschCW, et al Fecal microbiota transfer for multidrug-resistant gram-negatives: a clinical success combined with microbiological failure. Open Forum Infect Dis 2017; 4:ofx047.
26 Staley C , VaughnBP, GraizigerCT, et al Gut-sparing treatment of urinary tract infection in patients at high risk of Clostridium difficile infection. J Antimicrob Chemother 2017; 72 :522–8.27999027
27 Singh R , van NoodE, NieuwdorpM, et al Donor feces infusion for eradication of extended spectrum beta-lactamase producing Escherichia coli in a patient with end stage renal disease. Clin Microbiol Infect 2014; 20 :O977–8.24845223
28 Tariq R , ToshPK, PardiDS, et al Reduction in urinary tract infections in patients treated with fecal microbiota transplantation for recurrent Clostridioides difficile infection. Eur J Clin Microbiol Infect Dis 2023; 42 :1037–41.37351724
29 Thänert R , ReskeKA, HinkT, et al Comparative genomics of antibiotic-resistant uropathogens implicates three routes for recurrence of urinary tract infections. mBio 2019; 10: e01977-19.
30 Millan B , ParkH, HotteN, et al Fecal microbial transplants reduce antibiotic-resistant genes in patients with recurrent Clostridium difficile infection. Clin Infect Dis 2016; 62 :1479–86.27025836
31 Gopalsamy SN , WoodworthMH, WangT, et al The use of microbiome restoration therapeutics to eliminate intestinal colonization with multidrug-resistant organisms. Am J Med Sci 2018; 356 :433–40.30384952
32 Paul D , DasB. Gut microbiome in the emergence of antibiotic-resistant bacterial pathogens. Prog Mol Biol Transl Sci 2022; 192 :1–31.36280316
33 Bilsen MP , LambregtsMMC, van PrehnJ, et al Faecal microbiota replacement to eradicate antimicrobial resistant bacteria in the intestinal tract - a systematic review. Curr Opin Gastroenterol 2022; 38 :15–25.34636363
34 Seong H , LeeSK, CheonJH, et al Fecal microbiota transplantation for multidrug-resistant organism: efficacy and response prediction. J Infect 2020; 81 :719–25.32920061
35 Yoon YK , SuhJW, KangE-J, et al Efficacy and safety of fecal microbiota transplantation for decolonization of intestinal multidrug-resistant microorganism carriage: beyond Clostridioides difficile infection. Ann Med 2019; 51 :379–89.31468999
36 Jouhten H , MattilaE, ArkkilaP, et al Reduction of antibiotic resistance genes in intestinal microbiota of patients with recurrent Clostridium difficile infection after fecal microbiota transplantation. Clin Infect Dis 2016; 63 :710–1.27317794
37 Woodworth MH , ConradRE, HaldopoulosM, et al Fecal microbiota transplantation promotes reduction of antimicrobial resistance by strain replacement. Sci Transl Med 2023; 15 :eabo2750.37910603
38 Hyun J , LeeSK, CheonJH, et al Faecal microbiota transplantation reduces amounts of antibiotic resistance genes in patients with multidrug-resistant organisms. Antimicrob Resist Infect Control 2022; 11 :20.35093183
39 Bilinski J , GrzesiowskiP, SorensenN, et al Fecal microbiota transplantation in patients with blood disorders inhibits gut colonization with antibiotic-resistant bacteria: results of a prospective, single-center study. Clin Infect Dis 2017; 65 :364–70.28369341
40 Dinh A , FessiH, DuranC, et al Clearance of carbapenem-resistant Enterobacteriaceae vs vancomycin-resistant enterococci carriage after faecal microbiota transplant: a prospective comparative study. J Hosp Infect 2018; 99 :481–6.29477634
41 Huttner BD , de LastoursV, WassenbergM, et al A 5-day course of oral antibiotics followed by faecal transplantation to eradicate carriage of multidrug-resistant Enterobacteriaceae: a randomized clinical trial. Clin Microbiol Infect 2019; 25 :830–8.30616014
42 Vendrik KEW , de MeijTGJ, BökenkampA, et al Transmission of antibiotic-susceptible Escherichia coli causing urinary tract infections in a fecal microbiota transplantation recipient: consequences for donor screening? Open Forum Infect Dis 2022.
43 DeFilipp Z , BloomPP, Torres SotoM, et al Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant. N Engl J Med 2019; 381 :2043–50.31665575
44 Leung V , VincentC, EdensTJ, et al Antimicrobial resistance gene acquisition and depletion following fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Infect Dis 2018; 66 :456–7.29020222
45 Mrazek K , BereswillS, HeimesaatMM. Fecal microbiota transplantation decreases intestinal loads of multi-drug resistant Pseudomonas aeruginosa in murine carriers. Eur J Microbiol Immunol (Bp) 2019; 9 :14–22.30967971
46 Caballero S , CarterR, KeX, et al Distinct but spatially overlapping intestinal niches for vancomycin-resistant Enterococcus faecium and carbapenem-resistant Klebsiella pneumoniae. PLoS Pathog 2015; 11 :e1005132.26334306
47 Neugent ML , HulyalkarNV, NguyenVH, et al Advances in understanding the human urinary microbiome and its potential role in urinary tract infection. mBio 2020; 11: e00218-20.
48 Aragón IM , Herrera-ImbrodaB, Queipo-OrtuñoMI, et al The urinary tract microbiome in health and disease. Eur Urol Focus 2018; 4 :128–38.28753805
49 Ammitzbøll N , BauBPJ, Bundgaard-NielsenC, et al Pre- and postmenopausal women have different core urinary microbiota. Sci Rep 2021; 11 :2212.33500504
50 Hugenholtz F , van der VeerC, TerpstraML, et al Urine and vaginal microbiota compositions of postmenopausal and premenopausal women differ regardless of recurrent urinary tract infection and renal transplant status. Sci Rep 2022; 12 :2698.35177690
51 Wolfe AJ , BrubakerL. Urobiome updates: advances in urinary microbiome research. Nat Rev Urol 2019; 16 :73–4.30510275
52 Shah C , BaralR, BartaulaB, et al Virulence factors of uropathogenic Escherichia coli (UPEC) and correlation with antimicrobial resistance. BMC Microbiol 2019; 19 :204.31477018
53 Ackerman AL , UnderhillDM. The mycobiome of the human urinary tract: potential roles for fungi in urology. Ann Transl Med 2017; 5 :31.28217696
54 Behzadi P , BehzadiE, RanjbarR. Urinary tract infections and Candida albicans. Cent European J Urol 2015; 68 :96–101.
55 Nickel JC , StephensA, LandisJR, et al Urinary fungi associated with urinary symptom severity among women with interstitial cystitis/bladder pain syndrome (IC/BPS). World J Urol 2020; 38 :433–46.31028455
56 Josephs-Spaulding J , KroghTJ, RettigHC, et al Recurrent urinary tract infections: unraveling the complicated environment of uncomplicated rUTIs. Front Cell Infect Microbiol 2021; 11 :562525.34368008
57 Lewis AL , GilbertNM. Roles of the vagina and the vaginal microbiota in urinary tract infection: evidence from clinical correlations and experimental models. GMS Infect Dis 2020; 8 :Doc02.32373427
58 Perez-Carrasco V , Soriano-LermaA, SorianoM, et al Urinary microbiome: yin and yang of the urinary tract. Front Cell Infect Microbiol 2021; 11 :617002.34084752
59 Dominoni M , ScatignoAL, La VerdeM, et al Microbiota ecosystem in recurrent cystitis and the immunological microenvironment of urothelium. Healthcare (Basel) 2023; 11:525 .
60 Stapleton AE . The vaginal microbiota and urinary tract infection. Microbiol Spectr 2016; 4 .
61 Gilbert NM , O'BrienV, LewisAL. Transient microbiota exposures activate dormant Escherichia coli infection in the bladder and drive severe outcomes of recurrent disease. PLoS Pathog 2017; 13 :e1006238.28358889
62 Hooton TM , FihnSD, JohnsonC, et al Association between bacterial vaginosis and acute cystitis in women using diaphragms. Arch Intern Med 1989; 149 :1932–6.2673116
63 Sumati AH , SarithaNK. Association of urinary tract infection in women with bacterial vaginosis. J Glob Infect Dis 2009; 1 :151–2.20300409
64 Thomas-White KJ , GaoX, LinH, et al Urinary microbes and postoperative urinary tract infection risk in urogynecologic surgical patients. Int Urogynecol J 2018; 29 :1797–805.30267143
65 Navas-Nacher EL , DardickF, VenegasMF, et al Relatedness of Escherichia coli colonizing women longitudinally. Mol Urol 2001; 5 :31–6.11689149
66 Ferrante KL , WasendaEJ, JungCE, et al Vaginal estrogen for the prevention of recurrent urinary tract infection in postmenopausal women: a randomized clinical trial. Female Pelvic Med Reconstr Surg 2021; 27 :112–7.31232721
67 Pabich WL , FihnSD, StammWE, et al Prevalence and determinants of vaginal flora alterations in postmenopausal women. J Infect Dis 2003; 188 :1054–8.14513427
68 Johnson JA , DelaneyLF, OjhaV, et al Commensal urinary lactobacilli inhibit major uropathogens in vitro with heterogeneity at species and strain level. Front Cell Infect Microbiol 2022; 12 :870603.35811675
